Irreversible electroporation therapy in the liver: Longitudinal efficacy studies in a rat model of hepatocellular carcinoma

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1555-1563

  Guo, Yang ^a   Zhang, Yue ^a,b   Klein, Rachel ^a   Nijm, Grace M ^d   Sahakian, Alan V ^d   Omary, Reed A ^a,c   Yang, Guang Yu ^a   Larson, Andrew C ^a,b,c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b University of Illinois at Chicago   (United States)

^c Northwestern University   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CARCINOGENESIS; CONTROLLED STUDY; ELECTRODE; ELECTROPORATION; ELECTROSURGERY; FOLLOW UP; HISTOPATHOLOGY; IRREVERSIBLE ELECTROPORATION THERAPY; LIVER CELL CARCINOMA; LONGITUDINAL STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME;

ABLATION TECHNIQUES; ANIMALS; ANTIGENS, CD34; CARCINOMA, HEPATOCELLULAR; ELECTROCHEMOTHERAPY; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 76749119408     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3067     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48 Suppl 1:S20-37.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
4. Callstrom MR, Charboneau JW. Technologies for ablation of hepatocellular carcinoma. Gastroenterology 2008;134:1831-5.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
6. Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Hepatogastroenterology 2001;48: 20-4.
7. Tsai WL, Cheng JS, Lai KH, et al. Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma - a long-term follow-up study. Aliment Pharmacol Ther 2008;28:304-11.
8. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234: 961-7.
9. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 2009;249:20-5.
10. Liang P, Dong B, Yu X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology 2005;235:299-307.
11. Vogl TJ, Muller PK, Hammerstingl R, et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective results. Radiology 1995;196:257-65.
12. Hinshaw JL, Lee FT, Jr. Cryoablation for liver cancer. Tech Vasc Interv Radiol 2007;10:47-57.
13. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353-7.
14. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-8.
15. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-9.
16. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005;103:1201-9.
17. Harrison LE, Koneru B, Baramipour P, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003;197:759-64.
18. Rhim H. Complications of radiofrequency ablation in hepatocellular carcinoma. Abdom Imaging 2005;30:409-18.
19. Teratani T, Yoshida H, Shiina S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006;43:1101-8.
20. Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005;33:223-31.
21. Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 2007;6:295-300.
22. Al-Sakere B, Andre F, Bernat C, et al. Tumor ablation with irreversible electroporation. PLoS ONE 2007;2:e1135.
23. Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 2006;53:1409-15.
24. Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat 2005;4:699-705.
25. Lee EW, Loh CT, Kee ST. Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation. Technol Cancer Res Treat 2007;6:287-94.
26. Rubinsky J, Onik G, Mikus P, Rubinsky B. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J Urol 2008;180:2668-74.
27. Davalos RV, Rubinsky B. Temperature considerations during irreversible electroporation. Int J Heat Mass Transf 2008;51:5617-22. 28. Novikoff AB. A transplantable rat liver tumor induced by 4-dimethylaminoazobenzene. Cancer Res 1957;17:1010-27.
28. Miklavcic D, Semrov D, Mekid H, Mir LM. A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochim Biophys Acta 2000; 1523:73-83.
29. Edd JF, Davalos RV. Mathematical modeling of irreversible electroporation for treatment planning. Technol Cancer Res Treat 2007;6: 275-86.
30. Ju S, McLennan G, Bennett SL, et al. Technical aspects of imaging and transfemoral arterial treatment of N1-1 tumors in rats: an appropriate model to test the biology and therapeutic response to transarterial treatments of liver cancers. J Vasc Interv Radiol 2009;20: 410-4.
31. Therasse P, Arbuck SG, Eisenhauer EA, et al, European Organization for Research and Treatment of CancerNational Cancer Institute of the United StatesNational Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
32. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): WHO; 1979.
33. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 2005;47:1-16.
34. Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. APMIS 2004;112:413-30.
35. Yagi T, Hardin JA, Valenzuela YM, Miyoshi H, Gores GJ, Nyberg SL. Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. Hepatology 2001;33:1432-40.
36. Najimi M, Smets F, Sokal E. Hepatocyte apoptosis. Methods Mol Biol 2009;481:59-74.
37. Garin E, Denizot B, Roux J, et al. Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat. Lab Anim 2005;39:314-20.
38. Ahmed M, Lobo SM, Weinstein J, et al. Improved coagulation with saline solution pretreatment during radiofrequency tumor ablation in a canine model. J Vasc Interv Radiol 2002;13:717-24.
39. Goldberg SN, Hahn PF, Halpern EF, Fogle RM, Gazelle GS. Radiofrequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter. Radiology 1998;209:761-7.
40. Al-Sakere B, Bernat C, Andre F, et al. A study of the immunological response to tumor ablation with irreversible electroporation. Technol Cancer Res Treat 2007;6:301-6.
41. Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 2007;6:307-12.
42. Dodd GD III, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 2000;20:9-27.
43. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality-clinical implications. Technol Cancer Res Treat 2007; 6:37-48.